Medicina
Departamento
University of Verona
Verona, ItaliaPublicaciones en colaboración con investigadores/as de University of Verona (72)
2024
-
Correction to: Is antiviral treatment at the acute phase of COVID-19 effective for decreasing the risk of long-COVID? A systematic review (Infection, (2024), 52, 1, (43-58), 10.1007/s15010-023-02154-0)
Infection
-
Current management of SARS-CoV-2 infection in solid organ transplant recipients: Experience derived from an ESGICH–ESOT survey
Transplant Infectious Disease
-
Does the Impact of COVID-19 on Patients With Systemic Sclerosis Change Over Time?
Arthritis Care and Research, Vol. 76, Núm. 1, pp. 88-97
-
Is antiviral treatment at the acute phase of COVID-19 effective for decreasing the risk of long-COVID? A systematic review
Infection, Vol. 52, Núm. 1, pp. 43-58
2023
-
Erratum : World Allergy Organization Anaphylaxis Guidance 2020 [Japanese Journal of Allergology Vol.70 (2021) No.9 p.1211-1234]
Arerugi = [Allergy], Vol. 72, Núm. 3, pp. 314
-
Sarcopenic obesity research perspectives outlined by the sarcopenic obesity global leadership initiative (SOGLI) – Proceedings from the SOGLI consortium meeting in rome November 2022
Clinical Nutrition
2022
-
International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis
JAMA Dermatology, Vol. 158, Núm. 5, pp. 561-572
-
Proposal of 0.5 mg of protein/100 g of processed food as threshold for voluntary declaration of food allergen traces in processed food—A first step in an initiative to better inform patients and avoid fatal allergic reactions: A GA²LEN position paper
Allergy: European Journal of Allergy and Clinical Immunology, Vol. 77, Núm. 6, pp. 1736-1750
2021
-
Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study
Journal of Allergy and Clinical Immunology, Vol. 147, Núm. 1, pp. 60-71
-
Quantifying duration of proteinuria remission and association with clinical outcome in IgA nephropathy
Journal of the American Society of Nephrology, Vol. 32, Núm. 2
-
Safety and activity of the TGFβ receptor i kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer
Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 3
-
World Allergy Organization Anaphylaxis Guidance 2020
Arerugi = [Allergy], Vol. 70, Núm. 9, pp. 1211-1234
2020
-
A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohn’s disease
Scientific Reports, Vol. 10, Núm. 1
-
Antifungal susceptibility testing in Candida, Aspergillus and Cryptococcus infections: are the MICs useful for clinicians?
Clinical Microbiology and Infection, Vol. 26, Núm. 8, pp. 1024-1033
-
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus
Leukemia, Vol. 34, Núm. 9, pp. 2354-2363
-
Pediatric NMOSD: A Review and Position Statement on Approach to Work-Up and Diagnosis
Frontiers in Pediatrics, Vol. 8
-
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial
The Lancet Oncology, Vol. 21, Núm. 1, pp. 105-120
-
World allergy organization anaphylaxis guidance 2020
World Allergy Organization Journal, Vol. 13, Núm. 10
2019
-
GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways
Nature Communications, Vol. 10, Núm. 1
-
Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: A prospective cohort study
Annals of the Rheumatic Diseases, Vol. 78, Núm. 7, pp. 979-987